Skip to main content

Multicenter study of OPRM1 A118G and promoter-region DNA methylation associations with opioid outcomes and chronic postsurgical pain after pediatric musculoskeletal surgery

Publication ,  Journal Article
Upton, BA; Krolick, KN; Zhang, X; Pilipenko, V; Martin, LJ; Ji, H; Glynn, S; Barnett, K; Ganesh, A; Monitto, CL; Einhorn, LM; Ramamurthi, RJ ...
Published in: Pain Reports
October 16, 2024

Introduction: Mu opioid receptor gene (OPRM1) variant rs1799971 introduces a CpG site, which may influence DNA methylation (DNAm) and opioid/pain outcomes. Objectives: In this nested analysis, we investigated both OPRM1 A118G genotype and promoter/immediate downstream blood DNAm sequencing data for associations with opioid effects and chronic postsurgical pain (CPSP) in a surgical cohort. Methods: Prospectively recruited opioid naïve patients undergoing Nuss procedure or spinal fusion with rs1799971 genotypes (Illumina arrays), DNAm (next generation enzymatic methylation sequencing at Chr6:154,039,209-154,039,803) and outcomes—opioid analgesia (integrated opioid use 1 pain over postoperative days 0 and 1 normalized to surgery type), safety—respiratory depression (RD) in high opioid use groups, and CPSP (Numerical Rating Scale .3/10 2-12 months postsurgery)—were included. Linear and logistic regression were performed to test genetic and epigenetic associations, adjusted for sociodemographics, cell types, and analgesics. Results: In this cohort (N 5 112; 15.3 6 2.0 years, 50% female, 83% White, 55% had CPSP, 13% had RD), DNAm at Chr6: 154039216-154039217 was associated with CPSP (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.00-1.57; P 5 0.03), Chr6: 154039661-154039662 with acute integrated pain (b 5 220.9, 95% CI, 240.70 to 21.10, P 5 0.04), Chr6:154039520-154039521 (OR, 1.49; 95% CI, 1.09-2.03; P 5 0.01), and Chr6:154039571-154039572 (OR, 1.47; 95% CI, 1.08-2.01; P 5 0.02) with RD. Significant CpG sites were located in Repressed Polycomb chromatin states. Genotype was not associated with DNAm or outcomes. Conclusion: Our analyses support OPRM1 DNAm as predictors of acute and chronic pain/opioid outcomes in children after painful surgery. Study limitations included absent GG genotype, low sequencing coverage, and lack of correction for multiple testing.

Duke Scholars

Published In

Pain Reports

DOI

EISSN

2471-2531

Publication Date

October 16, 2024

Volume

9

Start / End Page

e1201

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Upton, B. A., Krolick, K. N., Zhang, X., Pilipenko, V., Martin, L. J., Ji, H., … Chidambaran, V. (2024). Multicenter study of OPRM1 A118G and promoter-region DNA methylation associations with opioid outcomes and chronic postsurgical pain after pediatric musculoskeletal surgery. Pain Reports, 9, e1201. https://doi.org/10.1097/PR9.0000000000001201
Upton, B. A., K. N. Krolick, X. Zhang, V. Pilipenko, L. J. Martin, H. Ji, S. Glynn, et al. “Multicenter study of OPRM1 A118G and promoter-region DNA methylation associations with opioid outcomes and chronic postsurgical pain after pediatric musculoskeletal surgery.” Pain Reports 9 (October 16, 2024): e1201. https://doi.org/10.1097/PR9.0000000000001201.
Upton BA, Krolick KN, Zhang X, Pilipenko V, Martin LJ, Ji H, Glynn S, Barnett K, Ganesh A, Monitto CL, Einhorn LM, Ramamurthi RJ, Chidambaran V. Multicenter study of OPRM1 A118G and promoter-region DNA methylation associations with opioid outcomes and chronic postsurgical pain after pediatric musculoskeletal surgery. Pain Reports. 2024 Oct 16;9:e1201.

Published In

Pain Reports

DOI

EISSN

2471-2531

Publication Date

October 16, 2024

Volume

9

Start / End Page

e1201

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences